December 11th, 2017
jobs
homes

Menu
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Virios Therapeutics, Inc. - Common Stock (NQ:VIRI)

0.1550 UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Virios Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (... 
Via Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Virios Therapeutics Announces Second Quarter 2021 Financial Results and Provides Corporate Update
From Virios Therapeutics, Inc.
Via Business Wire
Earnings Scheduled For August 12, 2021
Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter. • ITeos Therapeutics (NASDAQ:ITOS... 
Via Benzinga
Virios Therapeutics to Present at the SNN Network Summer Virtual Conference
From Virios Therapeutics, Inc. (VIRI)
Via Business Wire
Virios Therapeutics Featured in Bloomberg TV Interview
From Virios Therapeutics, Inc. (VIRI)
Via Business Wire
Virios Therapeutics to Report Second Quarter 2021 Financial Results and Provide Corporate Update on Thursday, August 12, 2021
From Virios Therapeutics, Inc. (VIRI)
Via Business Wire
Why Virios Therapeutics' Stock Is Trading Higher Today
Virios Therapeutics' (NASDAQ:VIRI) shares ar... 
Via Benzinga
Virios Therapeutics Highlights Clinical Sites Fully Operational in Phase 2b Fibromyalgia Study Featuring FDA “Fast Track” Review Designated Antiviral Therapy, Oral IMC-1
From Virios Therapeutics, Inc. (VIRI)
Via Business Wire
Fibromyalgia Treatment: 3 Pillars that Set Virios Therapeutics Apart from the Rest
The success of any company most often begins with a solid foundation and strong pillars. These two are essential ingredients to the growth of a company. Weak foundations or... 
Via Benzinga
Virios Therapeutics Stock Moves Higher On Promising IMC-1 Safety Data In Mid-Stage Fibromyalgia Trial
Virios Therapeutics Inc (NASDAQ: VIRI) has announced that data from its Phase 2a PRID-201 trial demonstrated that IMC-1 was better tolerated than placebo in... 
Via Benzinga
Virios Therapeutics Highlights Safety Data from Phase 2a Fibromyalgia Trial at the International Association for the Study of Pain (IASP) World Congress
From Virios Therapeutics, Inc.
Via Business Wire
62 Biggest Movers From Yesterday
Gainers Aethlon Medical, Inc. (NASDAQ: AEMD) shares surged 388.2% to close at $10.79 on Wednesday in reaction to Zacks Article 'AEMD: First Ever In Vivo Removal Of COVID... 
Via Benzinga
Virios Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating IMC-1 in Patients with Fibromyalgia
From Virios Therapeutics, Inc. (VIRI)
Via Business Wire
48 Stocks Moving In Wednesday's Mid-Day Session
Gainers Aethlon Medical, Inc. (NASDAQ: AEMD) shares jumped 371% to $10.41 in reaction to Zacks Article 'AEMD: First Ever In Vivo Removal Of COVID Virus From Bloodstream Of An... 
Via Benzinga
Virios Therapeutics Presents Phase 2a Fibromyalgia Trial Data on Efficacy Analyses of Key Secondary Endpoints at the EULAR European Congress of Rheumatology
From Virios Therapeutics, Inc. (VIRI)
Via Business Wire
Virios Therapeutics Announces Oral Presentation of Clinical Data at Digestive Disease Week® (DDW)
From Virios Therapeutics, Inc.
Via Business Wire
58 Biggest Movers From Yesterday
Gainers BM Technologies, Inc. (NYSE: BMTX) shares climbed 26.4% to close at $11.82 on Tuesday after the company reported record Q1 results. Ultralife Corporation (NASDAQ: ULBI)... 
Via Benzinga
Virios Therapeutics Announces First Quarter 2021 Financial Results and Provides Corporate Update
From Virios Therapeutics, Inc. (VIRI)
Via Business Wire
Virios Therapeutics to Present at the Benzinga Global Small Cap Conference
From Virios Therapeutics, Inc.
Via Business Wire
Virios Therapeutics to Report First Quarter 2021 Financial Results and Provide Corporate Update on Thursday, May 13, 2021
From Virios Therapeutics, Inc. (VIRI)
Via Business Wire
Earnings Scheduled For May 13, 2021
Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of $5.05 million. •... 
Via Benzinga
Virios Therapeutics, Inc. Interview to Air on Bloomberg Television U.S. on the RedChip Money Report
From Virios Therapeutics, Inc. (VIRI)
Via Business Wire
Virios Therapeutics to Present at the Needham Virtual Healthcare Conference
From Virios Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.